Physician profile
Daniel P Davis
NPI 1548204423
$361,237.87
in general payments reported to CMS, 2019-2025
9 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $31K · 2021: $130K · 2022: $123K · 2023: $630 · 2024: $6,951 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $6,867 · Travel and Lodging: $5,012 · Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,656.25 |
| Honoraria | $6,867.00 |
| Travel and Lodging | $5,012.19 |
| Food and Beverage | $407.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Medical Corporation | $293,104.65 | 2019-2022 | |
| Philips North America LLC | $26,139.13 | 2024-2025 | Aed Service, (5132) Rdt Sv Time Material, Rdt Sv Time Material |
| Masimo Corporation | $24,000.00 | 2020-2022 | |
| Covidien Lp | $16,884.53 | 2019 | |
| Stryker Corporation | $795.29 | 2022-2023 | Lifepak 15 Monitor/Defibrillator, Lucas |
| Integra Lifesciences Corporation | $157.96 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medline Industries Lp | $128.14 | 2021 | |
| Lilly USA, LLC | $16.05 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.